Express Pharma

Torrent Pharma launches Adfrar

3

Brand ‘Adfrar’ will be the second biosimilar Adalimumab in the world

Ahmedabad-based Torrent Pharma has launched biosimilar Adalimumab in India under the brand name ‘Adfrar’. Adalimumab is used for the treatment of auto immune disorders and has wide applications like rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis and plaque psoriasis. Torrent’s brand ‘Adfrar’ will be the second biosimilar Adalimumab in the world.

‘Adfrar’ will be available as pre-filled syringe of 40mg. Torrent will promote this biosimilar to rheumatologists, gastroenterologists and dermatologists pan India, for which three separate super specialty task force have been introduced. Around 100 trained professionals are employed in these greenfield divisions.

Comments are closed.